Device first used at OHI receives FDA approval
A device used for the first time in the world by cardiologists at Oklahoma Heart Institute, part of Hillcrest Medical Center, has now received authorization by the U.S. Food and Drug Administration (FDA).
The Edwards PASCAL Precision system is used in the treatment of severe degenerative mitral regurgitation (DMR) in patients who are high-risk for surgery. The device, with its independent grasping, atraumatic clasp and closure, and ability to elongate, enables safe and effective treatment for patients with DMR, according to Edwards Lifesciences Corporation.
